Improving efficacy and reducing toxicity of anti-PD-L1 treatment: T-cells as delivery vehicles for anti-PD-L1 blocking nanobodies

被引：0

作者：

Petit, P-F. ^{[1
]}

Zhu, J. ^{[1
]}

van den Eynde, B. J. ^{[1
]}

机构：

[1] Ludwig Inst Canc Res, De Duve Inst, Brussels, Belgium

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.10.511

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

25P

引用

页码：S1425 / S1425

页数：1

共 50 条

[31] Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies
Sun, J.
Yang, Q.
Chen, M.
Gu, J.
Zheng, L.
Yu, Y.
Li, F.
Zhang, L.
Niu, K.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S451 - S451
[32] ANTI-PD-1 AND ANTI-PD-L1 ANTIBODIES AS IMMUNOTHERAPY AGAINST CANCER: A STRUCTURAL PERSPECTIVE
Cordova-Bahena, Luis
Velasco-Velazquez, Marco A.
REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2021, 73 (01): : 8 - 16
[33] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
Kathryn Lurain
Ramya Ramaswami
Robert Yarchoan
Thomas S. Uldrick
Current HIV/AIDS Reports, 2020, 17 : 547 - 556
[34] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
Lurain, Kathryn
Ramaswami, Ramya
Yarchoan, Robert
Uldrick, Thomas S.
CURRENT HIV/AIDS REPORTS, 2020, 17 (05) : 547 - 556
[35] Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis Reply
Rivera, Noelia
Boada, Aram
Ferrandiz, Carlos
JAMA DERMATOLOGY, 2018, 154 (01) : 113 - 114
[36] Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
Boustani, Jihane
Lecoester, Benoit
Baude, Jeremy
Latour, Charlene
Adotevi, Olivier
Mirjolet, Celine
Truc, Gilles
CANCERS, 2021, 13 (19)
[37] Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1 /PD-1 immunotherapy
Ioannou, Nikolaos
Hagner, Patrick R.
Stokes, Matt
Gandhi, Anita K.
Apollonio, Benedetta
Fanous, Mariam
Papazoglou, Despoina
Sutton, Lesley-Ann
Rosenquist, Richard
Amini, Rose-Marie
Chiu, Hsiling
Lopez-Girona, Antonia
Janardhanan, Preethi
Awan, Farrukh T.
Jones, Jeffrey
Kay, Neil E.
Shanafelt, Tait D.
Tallman, Martin S.
Stamatopoulos, Kostas
Patten, Piers E. M.
Vardi, Anna
Ramsay, Alan G.
BLOOD, 2021, 137 (02) : 216 - 231
[38] Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection
Balsitis, Scott
Gali, Volodymyr
Mason, Pamela J.
Chaniewski, Susan
Levine, Steven M.
Wichroski, Michael J.
Feulner, Michael
Song, Yunling
Granaldi, Karen
Loy, James K.
Thompson, Chris M.
Lesniak, Jacob A.
Brockus, Catherine
Kishnani, Narendra
Menne, Stephan
Cockett, Mark I.
Iyer, Renuka
Mason, Stephen W.
Tenney, Daniel J.
PLOS ONE, 2018, 13 (02):
[39] Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Kowanetz, Marcin
Zou, Wei
Gettinger, Scott N.
Koeppen, Hartmut
Kockx, Mark
Schmid, Peter
Kadel, Edward E., III
Wistuba, Ignacio
Chaft, Jamie
Rizvi, Naiyer A.
Spigel, David R.
Spira, Alexander
Hirsch, Fred R.
Cohen, Victor
Smith, Dustin
Boyd, Zach
Miley, Natasha
Flynn, Susan
Leveque, Vincent
Shames, David S.
Ballinger, Marcus
Mocci, Simonetta
Shankar, Geetha
Funke, Roel
Hampton, Garret
Sandler, Alan
Amler, Lukas
Mellman, Ira
Chen, Daniel S.
Hegde, Priti S.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (43) : E10119 - E10126
[40] Metformin facilitates anti-PD-L1 efficacy through the regulation of intestinal microbiota
Zhao, Xiaopeng
Liu, Chuang
Peng, Licheng
Wang, Hongyan
GENES AND IMMUNITY, 2024, 25 (01) : 7 - 13

← 1 2 3 4 5 →